Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer

Strahlentherapie und Onkologie

Volumn 189, Issue 5, 2013, Pages 417-423

  Boda Heggemann, J ^a   Weiss, C ^a   Schneider, V ^a   Hofheinz, R D ^a   Haneder, S ^a   Michaely, H ^a   Wertz, H ^a   Ronellenfitsch, U ^a   Hochhaus, A ^b   Wenz, F ^a   Lohr, F ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Chemotherapy; Gastroesophageal junction; Radiotherapy; Renal function; Toxicity

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG SAFETY; FEMALE; FLATULENCE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; RADIOTHERAPY, CONFORMAL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84877818339     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0309-2     Document Type: Article

References (27)

1. Bleiberg H, Goffin JC, Dalesio O et al (1989) Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 15:535-543
2. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
3. Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-2333
4. Kim S, Lim DH, Lee J et al (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279-1285
5. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
6. Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715-1721
7. Hagen P van, Hulshof MC, Lanschot JJ van et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084
8. Leibl BJ, Vitz S, Schafer W et al (2011) Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol 187:231-237
9. Brunner T (2012) Despite of the updated analysis of the SWOG-directed Intergroup Study 0116, adjuvant radiochemotherapy is not yet the standard for gastric cancer after curative resection. Strahlenther Onkol 188(11):1052-1053
10. Lordick F (2012) Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial. Strahlenther Onkol 188:636-637
11. Guckenberger M (2012) Indications for neoadjuvant or definitive radiochemotherapy in esophageal cancer of the highest evidence quality. Strahlenther Onkol 188:949-950
12. Smalley SR, Gunderson L, Tepper J et al (2002) Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 52:283-293
13. Hofheinz RD, Wenz F, Lukan N et al (2009) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73:142-147
14. Boda-Heggemann J, Hofheinz RD, Weiss C et al (2009) Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. Int J Radiat Oncol Biol Phys 75:1187-1195
15. Jansen EP, Saunders MP, Boot H et al (2007) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67:781-785
16. Welz S, Hehr T, Kollmannsberger C et al (2007) Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys 69:1429-1435
17. Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1-11
18. Lohr F, Dobler B, Mai S et al (2003) Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 179:557-563
19. Wieland P, Dobler B, Mai S et al (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 59:1236-1244
20. Hofheinz RD, Wenz F, Lukan N et al (2008) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73(1):142-147
21. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
22. Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315-321
23. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856
24. Buergy D, Lohr F, Baack T et al (2012) Radiotherapy for tumors of the stomach and gastroesophageal junction - a review of its role in multimodal therapy. Radiat Oncol 7:192
25. Schuhmacher CP, Fink U, Becker K et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918-927
26. Haneder S, Michaely HJ, Schoenberg SO et al (2012) Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional (1)H-MRI and (23)Na-MRI. Strahlenther Onkol 188:1146-1154
27. Lee J, Lim do H, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273